Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- LDP Gathers Steam towards Pharma Policy Proposal Next Month, Sees Honebuto as Make-or-Break Milestone
April 18, 2023
- Abortion Pill Mefeego’s Japan Panel Review Rescheduled for April 21
April 18, 2023
- Expert Panel Proposal to Be Compiled at May-End: MHLW Official
April 18, 2023
- Relief Claims OK’ed for 12 More Deaths Possibly Linked to COVID Jabs
April 18, 2023
- Comprehensive Review of COVID Budgets Necessary: MOF Panel Chair
April 17, 2023
- Japan to Set Out Measures Against Hay Fever, Promote Curative Therapy
April 17, 2023
- Number of Mpox Cases Totals 109 in Japan: MHLW
April 17, 2023
- Japan to Map Out Substantive Policy to Solve Pharma Industry Issues: Minister
April 14, 2023
- Lower House Clears Bill to Amend Next-Gen Medical Infrastructure Law
April 14, 2023
- LDP Pharma Study Group to Draw Up Resolution in May before Honebuto Paper
April 13, 2023
- Lawmakers Split 50/50 on Abortion Pill, No Conclusion at LDP Panel
April 13, 2023
- Ultomiris’ NMOSD Nod Up for Advisory Panel Review on April 26
April 13, 2023
- Mpox Cases Top 100 in Japan, 10 New Patients Confirmed
April 13, 2023
- Pandemic Response Agency to Be Set Up as Early as September: Minister Goto
April 12, 2023
- Japan Aims to Cut Use of IV Carbapenem Antibiotics by 20%: AMR Action Plan
April 11, 2023
- LDP Project Team Calls for Price Maintenance During Patent Period and Rethink of Off-Year Cuts
April 11, 2023
- Skyrizi’s Palmoplantar Pustulosis Use on PAFSC Agenda on April 24
April 11, 2023
- 9-Valent HPV Vaccine Program Poses Opportunity to Boost Inoculation Rate: LDP Lawmaker
April 7, 2023
- Japan Needs Guidelines on Conditional Approval for Regenerative Medicines: Lawmakers
April 7, 2023
- Tokyo Likely to See Next COVID Spike around First Half of May: Experts
April 7, 2023
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…